NCT05005728 2025-07-17
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
Phase 2 Completed
Clinical Trials
14 trialsNCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT02598895 2022-11-17
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
University of Washington
Phase 2 Completed
NCT01051570 2020-12-01
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00049257 2020-09-01
Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00514540 2020-09-01
Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00017576 2017-04-28
Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00016913 2016-07-06
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00005627 2013-07-18
Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Phase 1 Completed
NCT00973882 2011-11-03
Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers
Centre Leon Berard
Phase 2 Completed
NCT00003690 2011-08-03
Flavopiridol Plus Cisplatin or Carboplatin in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Phase 1 Completed
NCT00193193 2010-08-04
Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00134706 2009-12-09
A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed